Stephens analyst Scott Fidel lowered the firm’s price target on Centene to $85 from $87 and keeps an Overweight rating on the shares. The firm’s prior view that Centene’s assumptions on Medicaid redeterminations are “meaningfully conservative” when compared to peers for 2023-2024 “remains fully intact” coming out of the Q2 report, the analyst tells investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNC: